The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.
 
Fangchao Zheng
No Relationships to Disclose
 
Feng Du
No Relationships to Disclose
 
Yongsheng Wang
No Relationships to Disclose
 
Xue Wang
No Relationships to Disclose
 
Jiayu Wang
No Relationships to Disclose
 
Jian Yue
No Relationships to Disclose
 
Fei Ma
No Relationships to Disclose
 
Ying Fan
No Relationships to Disclose
 
Binghe Xu
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Roche
Research Funding - Jiangsu Hengrui Medicine (Inst)
 
Peng Yuan
No Relationships to Disclose